Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Current Assets (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Current Assets data on record, last reported at $236.8 million in Q3 2025.

  • For Q3 2025, Current Assets rose 141.12% year-over-year to $236.8 million; the TTM value through Sep 2025 reached $236.8 million, up 141.12%, while the annual FY2024 figure was $115.5 million, 13.67% down from the prior year.
  • Current Assets reached $236.8 million in Q3 2025 per ASMB's latest filing, up from $77.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $236.8 million in Q3 2025 and bottomed at $49.7 million in Q3 2023.
  • Average Current Assets over 5 years is $127.2 million, with a median of $115.5 million recorded in 2024.
  • Peak YoY movement for Current Assets: tumbled 56.84% in 2023, then surged 141.12% in 2025.
  • A 5-year view of Current Assets shows it stood at $154.2 million in 2021, then crashed by 37.12% to $97.0 million in 2022, then skyrocketed by 37.97% to $133.8 million in 2023, then dropped by 13.67% to $115.5 million in 2024, then surged by 105.03% to $236.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $236.8 million in Q3 2025, $77.5 million in Q2 2025, and $95.5 million in Q1 2025.